FDA
-
-
-
-
-
-
-
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
-
-
-
-
-
-
-
MyMD Pharmaceuticals Secures Strategic Investments
-
-
-
-
-
-
-
MyMD Pharmaceuticals (MYMD) Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
-
-
-
-
-
-
-
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
-
-
-
-
-
-
-
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
-
-
-
-
-
-
-
MyMD Pharmaceuticals (MYMD) Advances Phase 2 Multi-Center Clinical Trial of MYMD-1
-
-
-
-
-
-
-
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
-
325,738 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

